Byetta Pancreatic Cancer Lawsuits: Bernstein Liebhard LLP Comments on Growing Reports Linking Byetta to Pancreatic Cancer, Pancreatitis, Thyroid Cancer

The Firm is investigating Byetta lawsuits on behalf of individuals treated with the type 2 diabetes drug who went on to develop pancreatic cancer, pancreatitis and thyroid cancer.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
We have heard from numerous Byetta patients who went on to develop pancreatic cancer, pancreatitis and thyroid cancer.

New York, New York (PRWEB) July 13, 2013

As Bernstein Liebhard LLP continues to investigate Byetta pancreatic cancer lawsuits, the firm notes that the drug has been the subject of a growing number of reports to the U.S. Food & Drug Administration (FDA) that involve pancreatic cancer, pancreatitis and thyroid cancer. According to the Institute for Safe Medicine Practices (ISMP), during a 12 month period that ended in June 2012, the FDA’s Adverse Event Reporting Database recorded 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer among patients taking Byetta. Among other things, the ISMP has recommended that the labels for Byetta and other type 2 diabetes drugs known as incretin mimetics be updated to include stronger alerts about these possible side effects, and that they be subjected to additional studies to examine their effects on the pancreas and thyroid.*

“We have heard from numerous Byetta patients who went on to develop pancreatic cancer, pancreatitis and thyroid cancer. The adverse event reports revealed by the ISMP are disturbing, and we agree with the group’s assessment that these issues need more study,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit evaluations to patients who took this drug and were diagnosed with pancreatic cancer, thyroid cancer or pancreatitis.

Byetta Lawsuits
Byetta and other incretin mimetics are the subject of a growing number of lawsuits that allege the drugs can cause pancreatitis, pancreatic cancer and thyroid cancer. According to court documents, a motion to consolidate all federal claims involving incretin mimetics, including Byetta lawsuits, in a single federal litigation for pretrial proceedings was filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) in April 2013. The JPML will hear Oral Arguments on the matter on July 25th. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

Brought to market in April of 2005, Byetta has raised concerns that it may have the potential to cause pancreatitis, pancreatic cancer and thyroid cancer. In 2008, for example, the FDA issued a public warning about Byetta after receiving a high number of reports involving pancreatitis.** In February 2011, research published in Gastroenterology suggested that Byetta could increase the risk of pancreatic cancer by 3-fold, and the risk of pancreatitis by 6-fold. The same study also reported 30 cases of thyroid cancer among Byetta patients.*** On March 14, 2013, the FDA announced it was investigating findings from an unpublished study that indicated drugs like Byetta could be associated with cellular changes in the pancreas called pancreatic duct metaplasia, a precursor to cancer.****

Byetta users who have been diagnosed with pancreatic cancer, pancreatitis, or thyroid cancer may be entitled to file a Byetta lawsuit seeking compensation for medical bills, lost wages, pain and suffering and other damages. To learn more about filing a Byetta pancreatic cancer lawsuit, visit Bernstein Liebhard LLP’s website. To arrange for a free case evaluation, please call 800-511-5092.

*ismp.org/quarterwatch/pdfs/2012Q3.pdf, ISMP, April 2013
**fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm; FDA, August 18, 2008
** *gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
****fda.gov/Drugs/DrugSafety/ucm343187.htm, FDA, March 14, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.byettalawsuit2013.com/


Contact

Follow us on: Contact's Twitter Contact's Google Plus